세계 정밀 암 진단검사 시장 규모는 2034년까지 16.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.
암 진단에서 액체 생검의 채택이 증가함에 따라 시장 경쟁이 치열해지고 있으며, 이 분야에 적극적으로 진출하는 기업들은 임상 발전의 중요한 원동력으로 간주되고 있습니다. 순환 종양 DNA 및 기타 마커에 초점을 맞춘 비침습적 액체 생검의 개발이 진행되고 있으며, 실시간 모니터링과 조기 발견을 가능하게 함으로써 암 진단을 혁신적으로 변화시킬 것으로 기대되고 있습니다.
한편, 정밀 암 진단검사는 차세대 염기서열 분석(NGS) 및 질량 분석과 같은 첨단 기술을 사용하지만, 이는 비용이 많이 들 수 있으며, 특히 자원이 부족한 지역에서는 접근성에 문제가 될 수 있습니다. 정밀 암 진단과 관련된 고비용은 시장 성장의 걸림돌로 작용할 수 있으며, 이러한 첨단 진단 도구의 환자 접근성을 제한할 수 있습니다. 정밀 암 진단이 보다 정확한 진단과 맞춤형 치료 계획과 같은 큰 이점에도 불구하고, 이러한 검사와 관련된 금전적 영향은 의료 시스템과 환자 모두에게 어려운 도전이 되고 있습니다.
세계 정밀 암 진단검사 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 보고서 개요
제2장 주요 요약
제3장 시장 개요
- 주요 조사 결과
- 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 과제
- COVID-19의 영향 분석
- Porter의 Five Forces 분석
- PEST 분석
제4장 정밀 암 진단검사 시장 분석 : 제품 및 서비스별
- 주요 조사 결과
- 시장의 매력 지수
- 시장 규모 추이와 예측
- 제품
- 서비스
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
제5장 정밀 암 진단검사 시장 분석 : 검사 유형별
- 주요 조사 결과
- 시장의 매력 지수
- 시장 규모 추이와 예측
- 암 영상 처리
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
- 컴퓨터 단층촬영
- 자기공명영상
- 디지털 및 아날로그 맘모그래피
- 양전자 방출 단층촬영
- 디지털 유방 토모신테시스
- 유방 분자 이미징
- 기타
- 분자 암 검사
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
- 중합효소 연쇄반응(PCR)
- 차세대 시퀀싱(NGS)
- 액체생검
- 면역조직화학(IHC)
- Fluorescence In Situ Hybridization(FISH)
- 기타
- 종양 마커 면역측정법
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
- POC 결장 암 검사
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
- 기타
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
제6장 정밀 암 진단검사 시장 분석 : 용도별
- 주요 조사 결과
- 시장의 매력 지수
- 시장 규모 추이와 예측
- 유방암
- 폐암
- 결장직장암
- 흑색종
- 췌장암
- 기타
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
제7장 정밀 암 진단검사 시장 분석 : 생검법별
- 주요 조사 결과
- 시장의 매력 지수
- 시장 규모 추이와 예측
- 액체 생검
- 조직 생검
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
제8장 정밀 암 진단검사 시장 분석 : 최종사용자별
- 주요 조사 결과
- 시장의 매력 지수
- 시장 규모 추이와 예측
- 진단 실험실
- 병원
- 암센터 및 클리닉
- 연구기관
- 시장 규모 추이와 예측 : 지역별
- 시장 점유율 : 지역별
제9장 정밀 암 진단검사 시장 분석 : 지역별
제10장 북미의 정밀 암 진단검사 시장 분석
제11장 유럽의 정밀 암 진단검사 시장 분석
제12장 아시아의 정밀 암 진단검사 시장 분석
제13장 라틴아메리카의 정밀 암 진단검사 시장 분석
제14장 중동 및 아프리카의 정밀 암 진단검사 시장 분석
제15장 기업 개요
- 시장 점유율 분석
- 전략적 전망
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Abbott
- QIAGEN N.V.
- Thermo Fisher Scientific
- bioMerieux SA
- Siemens Healthineers
- Bayer AG
- Myriad Genetics, Inc.
- Agilent Technologies, Inc.
제16장 결론 및 추천 사항
- Visiongain의 결론
- 참여 기업을 위한 추천 사항
LSH
The global Precision Cancer Diagnostic Test Market is projected to grow at a CAGR of 16.1% by 2034.
“The Precision Cancer Diagnostic Test Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increasing Adoption of Liquid Biopsies Propels Market Growth
The increasing adoption of liquid biopsies in cancer diagnosis has significantly intensified market competitiveness, with companies actively entering this domain viewed as key drivers of clinical advancements. LabCorp's introduction of a novel blood test in June 2023 for detecting cancer-related biomarkers exemplifies this trend, potentially expediting effective treatments. Liquid biopsy, particularly valuable for those unable to undergo tissue biopsies, is gaining traction, notably in diagnosing advanced and metastatic cancer cases. Breakthroughs, such as the detection of cancer in diverse bodily fluids through liquid biopsy in March 2022, highlight the technology's expanding applications. The ongoing development of non-invasive liquid biopsies focusing on circulating tumor DNA and other markers holds promise for transforming cancer diagnostics by enabling real-time monitoring and early detection. Industry efforts to integrate liquid biopsy with advanced AI technologies, as seen in collaborations like GC Genome Corporation with KAIST, underscore the commitment to enhancing DNA mutation analysis. Noteworthy company initiatives, including Qiagen's acquisition of Verogen and BillionToOne's precise liquid biopsy device launch, highlights the industry's focus on growth, technological advancements, and product innovation, driving market expansion.
Challenges Posed by High Cost of Precision Cancer Diagnostic Test
Precision cancer diagnostic tests utilize advanced technologies, such as next-generation sequencing (NGS) or mass spectrometry, which can be associated with high costs, posing challenges for accessibility, especially in resource-constrained regions. The elevated expenses linked to precision cancer diagnostics may act as a hindrance to market growth, restricting patient access to these advanced diagnostic tools. Despite the significant advantages offered by precision cancer diagnostics, including more accurate diagnoses and personalized treatment plans, the financial implications associated with these tests presents a formidable challenge for both healthcare systems and patients. For example, the FoundationOne CDx, priced at approximately US$5,800.0 per biopsy, delivers valuable information for treatment decisions but can impose a substantial financial burden on patients and healthcare systems. Guardant360, a liquid biopsy test by Guardant Health analyzing circulating tumor DNA, comes with a cost ranging from US$5,000 to US$6,500 per biopsy. While liquid biopsies are less invasive than tissue biopsies, their pricing remains a concern, potentially limiting access for certain patients, particularly those lacking comprehensive insurance coverage, and leading to potential delays in diagnosis and treatment decisions.
What Questions Should You Ask before Buying a Market Research Report?
- How is the precision cancer diagnostic test market evolving?
- What is driving and restraining the precision cancer diagnostic test market?
- How will each precision cancer diagnostic test submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each precision cancer diagnostic test submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading precision cancer diagnostic test markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the precision cancer diagnostic test projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of precision cancer diagnostic test projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the precision cancer diagnostic test market?
- Where is the precision cancer diagnostic test market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the precision cancer diagnostic test market today, and over the next 10 years:
- Our 370-page report provides 135 tables and 235 charts/graphs exclusively to you
- The report highlights key lucrative areas in the industry so you can target them - NOW
- It contains in-depth analysis of global, regional and national sales and growth
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the precision cancer diagnostic test market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
- You will find original analyses, with business outlooks and developments
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision cancer diagnostic test prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Product & Services Outlook
Test Type
- Cancer Imaging
- Computed Tomography
- Magnetic Resonance Imaging
- Digital & Analog Mammography
- Positron Emission Tomography
- Digital Breast Tomosynthesis
- Molecular Breast Imaging
- Others
- Molecular Cancer Testing
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Liquid Biopsies
- Immunohistochemistry (IHC)
- Fluorescence In Situ Hybridization (FISH)
- Others
- Tumour Marker Immunoassays
- POC Colon Cancer Tests
- Others
Biopsy Method
- Liquid Biopsy
- Tissue Biopsy
Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Pancreatic Cancer
- Other Cancers
End-user
- Diagnostic Laboratories
- Hospitals
- Cancer Centers and Clinics
- Research Institutions
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:
North America
Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Precision Cancer Diagnostic Test Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report:
- Abbott
- Agilent Technologies, Inc.
- Bayer AG
- bioMerieux SA
- F. Hoffmann-La Roche Ltd.
|
- Illumina, Inc.
- Myriad Genetics, Inc.
- QIAGEN N.V
- Siemens Healthineers
- Thermo Fisher Scientific
|
Overall world revenue for Precision Cancer Diagnostic Test Market, 2024 to 2034 in terms of value the market will surpass US$12,097.8 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the “Precision Cancer Diagnostic Test Market, 2024 to 2034” report help you?
In summary, our 370-page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Precision Cancer Diagnostic Test Market, 2024 to 2034 Market, with forecasts for product, test type, application, biopsy method, and end-user, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 18 key national markets - See forecasts for the Precision Cancer Diagnostic Test Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also includes forecast for the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Precision Cancer Diagnostic Test Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Precision Cancer Diagnostic Test Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Precision Cancer Diagnostic Test Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Advancements in Genomic Research
- 3.2.1.2 High Demand for Personalized Healthcare
- 3.2.1.3 Rising Prevalence of Cancer
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Regulatory Hurdles
3.2.2.2High Cost of Precision Cancer Diagnostic Tests
- 3.2.3 Market Opportunities
- 3.2.3.1 Integration of AI and Machine Learning for Cancer Diagnosis
- 3.2.3.2 Rising Adoption of Liquid Biopsies
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
3.4.1Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat from Substitutes
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
4 Precision Cancer Diagnostic Test Market Analysis by Products & Services
- 4.1 Key Findings
- 4.2 Product Segment: Market Attractiveness Index
- 4.3 Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 4.4 Products
- 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Services
- 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Precision Cancer Diagnostic Test Market Analysis by Test Type
- 5.1 Key Findings
- 5.2 Test Type Segment: Market Attractiveness Index
- 5.3 Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 5.4 Cancer Imaging
- 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.3 Computed Tomography
- 5.4.3.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.3.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.4 Magnetic Resonance Imaging
- 5.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.5 Digital & Analog Mammography
- 5.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.6 Positron Emission Tomography
- 5.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.6.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.7 Digital Breast Tomosynthesis
- 5.4.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.7.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.8 Molecular Breast Imaging
- 5.4.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.8.2 Market Share by Region, 2024 & 2034 (%)
- 5.4.9 Others
- 5.4.9.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.9.2 Market Share by Region, 2024 & 2034 (%)
- 5.5 Molecular Cancer Testing
- 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.3 Polymerase Chain Reaction (PCR)
- 5.5.3.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.3.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.4 Next-Generation Sequencing (NGS)
- 5.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.5 Liquid Biopsies
- 5.5.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.6 Immunohistochemistry (IHC)
- 5.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.6.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.7 Fluorescence In Situ Hybridization (FISH)
- 5.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.7.2 Market Share by Region, 2024 & 2034 (%)
- 5.5.8 Others
- 5.5.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.8.2 Market Share by Region, 2024 & 2034 (%)
- 5.6 Tumour Marker Immunoassays
- 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.6.2 Market Share by Region, 2024 & 2034 (%)
- 5.7 POC Colon Cancer Tests
- 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.7.2 Market Share by Region, 2024 & 2034 (%)
- 5.8 Others
- 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.8.2 Market Share by Region, 2024 & 2034 (%)
6 Precision Cancer Diagnostic Test Market Analysis by Application
- 6.1 Key Findings
- 6.2 Application Segment: Market Attractiveness Index
- 6.3 Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 6.4 Breast Cancer
- 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.4.2 Market Share by Region, 2024 & 2034 (%)
- 6.5 Lung Cancer
- 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)
- 6.6 Colorectal Cancer
- 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.6.2 Market Share by Region, 2024 & 2034 (%)
- 6.7 Melanoma
- 6.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.7.2 Market Share by Region, 2024 & 2034 (%)
- 6.8 Pancreatic Cancer
- 6.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.8.2 Market Share by Region, 2024 & 2034 (%)
- 6.9 Other Cancers
- 6.9.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.9.2 Market Share by Region, 2024 & 2034 (%)
7 Precision Cancer Diagnostic Test Market Analysis by Biopsy Method
- 7.1 Key Findings
- 7.2 Biopsy Method Segment: Market Attractiveness Index
- 7.3 Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 7.4 Liquid Biopsy
- 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.4.2 Market Share by Region, 2024 & 2034 (%)
- 7.5 Tissue Biopsy
- 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.5.2 Market Share by Region, 2024 & 2034 (%)
8 Precision Cancer Diagnostic Test Market Analysis by End-user
- 8.1 Key Findings
- 8.2 End-users Segment: Market Attractiveness Index
- 8.3 Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
- 8.4 Diagnostic Laboratories
- 8.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.4.2 Market Share by Region, 2024 & 2034 (%)
- 8.5 Hospitals
- 8.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.5.2 Market Share by Region, 2024 & 2034 (%)
- 8.6 Cancer Centers and Clinics
- 8.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.6.2 Market Share by Region, 2024 & 2034 (%)
- 8.7 Research Institutions
- 8.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.7.2 Market Share by Region, 2024 & 2034 (%)
9 Precision Cancer Diagnostic Test Market Analysis by Region
- 9.1 Key Findings
- 9.2 Regional Market Size Estimation and Forecast
10 North America Precision Cancer Diagnostic Test Market Analysis
- 10.1 Key Findings
- 10.2 North America Precision Cancer Diagnostic Test Market Attractiveness Index
- 10.3 North America Precision Cancer Diagnostic Test Market by Country, 2024, 2029 & 2034 (US$ Million)
- 10.4 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Country
- 10.5 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 10.6 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 10.6.1 North America Cancer Imaging Market Size Estimation and Forecast by Type
- 10.6.2 North America Molecular Cancer Testing Market Size Estimation and Forecast by Type
- 10.7 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 10.8 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 10.9 North America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
- 10.10 U.S. Precision Cancer Diagnostic Test Market Analysis
- 10.11 Canada Precision Cancer Diagnostic Test Market Analysis
11 Europe Precision Cancer Diagnostic Test Market Analysis
- 11.1 Key Findings
- 11.2 Europe Precision Cancer Diagnostic Test Market Attractiveness Index
- 11.3 Europe Precision Cancer Diagnostic Test Market by Country, 2024, 2029 & 2034 (US$ Million)
- 11.4 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Country
- 11.5 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 11.6 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 11.6.1 Europe Cancer Imaging Market Size Estimation and Forecast by Type
- 11.6.2 Europe Molecular Cancer Testing Market Size Estimation and Forecast by Type
- 11.7 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 11.8 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 11.9 Europe Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
- 11.10 Germany Precision Cancer Diagnostic Test Market Analysis
- 11.11 UK Precision Cancer Diagnostic Test Market Analysis
- 11.12 France Precision Cancer Diagnostic Test Market Analysis
- 11.13 Italy Precision Cancer Diagnostic Test Market Analysis
- 11.14 Spain Precision Cancer Diagnostic Test Market Analysis
- 11.15 Russia Precision Cancer Diagnostic Test Market Analysis
- 11.16 Rest of Europe Precision Cancer Diagnostic Test Market Analysis
12 Asia Precision Cancer Diagnostic Test Market Analysis
- 12.1 Key Findings
- 12.2 Asia Precision Cancer Diagnostic Test Market Attractiveness Index
- 12.3 Asia Precision Cancer Diagnostic Test Market by Country, 2024, 2029 & 2034 (US$ Million)
- 12.4 Asia Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Country
- 12.5 Asia Pacific Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 12.6 Asia Pacific Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 12.6.1 Asia Pacific Cancer Imaging Market Size Estimation and Forecast by Type
- 12.6.2 Asia Pacific Molecular Cancer Testing Market Size Estimation and Forecast by Type
- 12.7 Asia Pacific Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 12.8 Asia Pacific Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 12.9 Asia Pacific Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
12.10Japan Precision Cancer Diagnostic Test Market Analysis
12.11China Precision Cancer Diagnostic Test Market Analysis
12.12India Precision Cancer Diagnostic Test Market Analysis
12.13Australia Precision Cancer Diagnostic Test Market Analysis
12.14South Korea Precision Cancer Diagnostic Test Market Analysis
12.15Rest of Asia Precision Cancer Diagnostic Test Market Analysis
13 Latin America Precision Cancer Diagnostic Test Market Analysis
- 13.1 Key Findings
- 13.2 Latin America Precision Cancer Diagnostic Test Market Attractiveness Index
- 13.3 Latin America Precision Cancer Diagnostic Test Market by Country, 2024, 2029 & 2034 (US$ Million)
- 13.4 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Country
- 13.5 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 13.6 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 13.6.1 Latin America Cancer Imaging Market Size Estimation and Forecast by Type
- 13.6.2 Latin America Molecular Cancer Testing Market Size Estimation and Forecast by Type
- 13.7 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 13.8 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 13.9 Latin America Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
13.10Brazil Precision Cancer Diagnostic Test Market Analysis
13.11Mexico Precision Cancer Diagnostic Test Market Analysis
13.12Argentina Precision Cancer Diagnostic Test Market Analysis
13.13Rest of Latin America Precision Cancer Diagnostic Test Market Analysis
14 MEA Precision Cancer Diagnostic Test Market Analysis
- 14.1 Key Findings
- 14.2 MEA Precision Cancer Diagnostic Test Market Attractiveness Index
- 14.3 MEA Precision Cancer Diagnostic Test Market by Country, 2024, 2029 & 2034 (US$ Million)
- 14.4 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Country
- 14.5 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Products & Services
- 14.6 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Test Type
- 14.6.1 MEA Cancer Imaging Market Size Estimation and Forecast by Type
- 14.6.2 MEA Molecular Cancer Testing Market Size Estimation and Forecast by Type
- 14.7 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Application
- 14.8 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by Biopsy Method
- 14.9 MEA Precision Cancer Diagnostic Test Market Size Estimation and Forecast by End-user
- 14.10 GCC Precision Cancer Diagnostic Test Market Analysis
- 14.11 South Africa Precision Cancer Diagnostic Test Market Analysis
- 14.12 Rest of MEA Precision Cancer Diagnostic Test Market Analysis
15 Company Profiles
- 15.1 Company Share Analysis, 2023
- 15.2 Strategic Outlook
- 15.3 F. Hoffmann-La Roche Ltd.
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2017-2022
- 15.3.3.2 R&D, 2017-2022
- 15.3.4 Product Benchmarking
- 15.3.5 Strategic Outlook
- 15.4 Illumina, Inc.
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
- 15.4.3.1 Net Revenue, 2017-2022
- 15.4.3.2 R&D, 2017-2022
- 15.4.3.3 Regional Market Shares, 2022
- 15.4.4 Product Benchmarking
- 15.4.5 Strategic Outlook
- 15.5 Abbott
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2017-2022
- 15.5.3.2 R&D, 2017-2022
- 15.5.3.3 Regional Market Shares, 2022
- 15.5.4 Product Benchmarking
- 15.5.5 Strategic Outlook
- 15.6 QIAGEN N.V.
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
- 15.6.3.1 Net Revenue, 2017-2022
- 15.6.3.2 R&D, 2017-2022
- 15.6.4 Product Benchmarking
- 15.6.5 Strategic Outlook
- 15.7 Thermo Fisher Scientific
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2017-2022
- 15.7.3.2 R&D, 2017-2022
- 15.7.3.3 Regional Market Shares, 2022
- 15.7.4 Product Benchmarking
- 15.7.5 Strategic Outlook
- 15.8 bioMerieux SA
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Financial Analysis
- 15.8.3.1 Net Revenue, 2017-2022
- 15.8.3.2 R&D, 2017-2022
- 15.8.3.3 Regional Market Shares, 2022
- 15.8.4 Product Benchmarking
- 15.9 Siemens Healthineers
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Financial Analysis
- 15.9.3.1 Net Revenue, 2017-2022
- 15.9.3.2 R&D, 2017-2022
- 15.9.4 Product Benchmarking
- 15.9.5 Strategic Outlook
- 15.10 Bayer AG
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
- 15.10.3.1 Net Revenue, 2017-2022
- 15.10.3.2 R&D, 2017-2022
- 15.10.3.3 Regional Market Shares, 2022
- 15.10.4 Product Benchmarking
- 15.10.5 Strategic Outlook
- 15.11 Myriad Genetics, Inc.
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Financial Analysis
- 15.11.3.1 Net Revenue, 2017-2022
- 15.11.3.2 R&D, 2017-2022
- 15.11.4 Product Benchmarking
- 15.11.5 Strategic Outlook
- 15.12 Agilent Technologies, Inc.
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Financial Analysis
- 15.12.3.1 Net Revenue, 2017-2022
- 15.12.3.2 R&D, 2017-2022
- 15.12.3.3 Regional Market Shares, 2022
- 15.12.4 Product Benchmarking
- 15.12.5 Strategic Outlook
16 Conclusion and Recommendations
- 16.1 Concluding Remarks from Visiongain
- 16.2 Recommendations for Market Players
